|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007226,
umls-concept:C0008976,
umls-concept:C0029456,
umls-concept:C0043210,
umls-concept:C0220825,
umls-concept:C0232970,
umls-concept:C0441471,
umls-concept:C0963839,
umls-concept:C1137094,
umls-concept:C1274040,
umls-concept:C1709628
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2010-10-26
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
In the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary heart disease (CHD) events and stroke, whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke. Both doses of lasofoxifene increased the risk of venous thromboembolic events. In this report, we provide comprehensive cardiovascular end-point data, including component events comprising the composite end point of major CHD events, and evaluate whether the effect of lasofoxifene 0.5 mg/d is consistent across different categories of CHD risk.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
pubmed-author:ArmstrongRoisinR,
pubmed-author:Barrett-ConnorElizabethE,
pubmed-author:CauleyJaneJ,
pubmed-author:CummingsStevenS,
pubmed-author:EastellRichardR,
pubmed-author:EnsrudKristineK,
pubmed-author:LaCroixAndreaA,
pubmed-author:ReidDavid MDM,
pubmed-author:ThompsonDavid DDD,
pubmed-author:ThompsonJohn RJR,
pubmed-author:VukicevicSlobodanS,
pubmed-author:WeltyFrancineF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
26
|
|
pubmed:volume |
122
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1716-24
|
|
pubmed:meshHeading |
pubmed-meshheading:20937977-Aged,
pubmed-meshheading:20937977-Aged, 80 and over,
pubmed-meshheading:20937977-Breast Neoplasms,
pubmed-meshheading:20937977-Coronary Disease,
pubmed-meshheading:20937977-Dose-Response Relationship, Drug,
pubmed-meshheading:20937977-Double-Blind Method,
pubmed-meshheading:20937977-Endpoint Determination,
pubmed-meshheading:20937977-Female,
pubmed-meshheading:20937977-Follow-Up Studies,
pubmed-meshheading:20937977-Fractures, Bone,
pubmed-meshheading:20937977-Humans,
pubmed-meshheading:20937977-Incidence,
pubmed-meshheading:20937977-Longitudinal Studies,
pubmed-meshheading:20937977-Middle Aged,
pubmed-meshheading:20937977-Osteoporosis, Postmenopausal,
pubmed-meshheading:20937977-Pyrrolidines,
pubmed-meshheading:20937977-Receptors, Estrogen,
pubmed-meshheading:20937977-Risk Factors,
pubmed-meshheading:20937977-Stroke,
pubmed-meshheading:20937977-Tetrahydronaphthalenes,
pubmed-meshheading:20937977-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
|
|
pubmed:affiliation |
VA Medical Center, Minneapolis, MN, USA. ensru001@umn.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
